Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT and Pembrolizumab in PD-1 Refractory Advanced Melanoma
NCT03341143Phase 2Completed
- Start
- Mar 2018
- Primary completion
- Sep 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fecal microbiome transplant in melanoma. Primary endpoint: Objective Response Rate up to 3 years. Started Mar 2018; status: completed.
02
Drugs
fecal microbiome transplant
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03341143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341143.